135 related articles for article (PubMed ID: 2359343)
1. Suitability of a new stable acetal analogue of aldoifosphamide for purging leukemic cells from human bone marrow.
Andersson BS; Wang YQ; McCredie KB; Farquhar D
Leukemia; 1990 Jun; 4(6):435-40. PubMed ID: 2359343
[TBL] [Abstract][Full Text] [Related]
2. The effects of acetaldophosphamide, a novel stable aldophosphamide analogue, on normal human and leukemic progenitor cells in vitro: implications for use in bone marrow purging.
Beran M; Andersson BS; Wang Y; McCredie KB; Farquhar D
Cancer Res; 1988 Jan; 48(2):339-45. PubMed ID: 3275495
[TBL] [Abstract][Full Text] [Related]
3. In vitro sensitivity of human hematopoietic progenitor cells to 4-hydroperoxycyclophosphamide.
Ratajczak MZ; Ratajczak J; Kuczynski W; Light B; Lusk EJ; Gewirtz AM
Exp Hematol; 1993 Dec; 21(13):1663-7. PubMed ID: 8243568
[TBL] [Abstract][Full Text] [Related]
4. Combinations of 4-hydroperoxycyclophosphamide (4-HC) and cisplatin for bone marrow purging in autologous marrow transplantation: an update.
Peters RH; Brandon CS; Avila LA; Gale GR; Stuart RK
Prog Clin Biol Res; 1990; 333():57-68. PubMed ID: 2309001
[TBL] [Abstract][Full Text] [Related]
5. Differential sensitivity of adherent CFU-blast, CFU-mix, BFU-E, and CFU-GM to mafosfamide: implications for adjusted dose purging in autologous bone marrow transplantation.
Carlo-Stella C; Mangoni L; Almici C; Garau D; Craviotto L; Piovani G; Caramatti C; Rizzoli V
Exp Hematol; 1992 Mar; 20(3):328-33. PubMed ID: 1568448
[TBL] [Abstract][Full Text] [Related]
6. TGF-beta 3 protects normal human hematopoietic progenitor cells treated with 4-hydroperoxycyclophosphamide in vitro.
Lemoli RM; Strife A; Clarkson BD; Haley JD; Gulati SC
Exp Hematol; 1992 Dec; 20(11):1252-6. PubMed ID: 1493854
[TBL] [Abstract][Full Text] [Related]
7. Regrowth of granulocyte-macrophage progenitor cells (GM-CFC) in suspension cultures of bone marrow depleted of GM-CFC with 4-hydroperoxycyclophosphamide (4-HC).
Beran M; Zander AR; Andersson BS; McCredie KB
Eur J Haematol; 1987 Aug; 39(2):118-24. PubMed ID: 3666100
[TBL] [Abstract][Full Text] [Related]
8. The effect of a prolonged in vitro exposure to 1-beta-D arabinofuranosylcytosine and deoxycytidine on the survival of normal (CFU-GM) and leukemic (L-CFU) human myeloid progenitor cells in suspension culture.
Grant S; Bhalla K; Arlin Z; Howe CW
Exp Hematol; 1990 Jan; 18(1):41-8. PubMed ID: 2298268
[TBL] [Abstract][Full Text] [Related]
9. Effect of combined treatment with interleukin-3 and interleukin-6 on 4-hydroperoxycyclophosphamide-mediated reduction of glutathione levels and cytotoxicity in normal and leukemic bone marrow progenitor cells.
Bhalla K; Bullock G; Lutzky J; Holladay C; Ibrado AM; Jasiok M; Singh S
Leukemia; 1992 Aug; 6(8):814-9. PubMed ID: 1640734
[TBL] [Abstract][Full Text] [Related]
10. Comparison of the sensitivity of normal and leukaemic myeloid progenitors to in-vitro incubation with cytotoxic drugs: a study of pharmacological purging.
Singer CR; Linch DC
Leuk Res; 1987; 11(11):953-9. PubMed ID: 3320579
[TBL] [Abstract][Full Text] [Related]
11. Potential drugs for elimination of acute lymphatic leukemia cells from autologous bone marrow.
Blaauw A; Spitzer G; Dicke K; Drewinko B; Vellekoop L; Zander A
Exp Hematol; 1986 Aug; 14(7):683-8. PubMed ID: 2426131
[TBL] [Abstract][Full Text] [Related]
12. Cumulative chemotherapy increases mafosfamide toxicity for normal progenitor cells in AML patients: rationale for cryopreserving adapted-dose purged marrow early in first complete remission.
Martin H; Bruecher J; Claudé R; Hoelzer D
Bone Marrow Transplant; 1993 Nov; 12(5):495-9. PubMed ID: 8298560
[TBL] [Abstract][Full Text] [Related]
13. Effects of verapamil on etoposide, vincristine, and adriamycin activity in normal human bone marrow granulocyte-macrophage progenitors and in human K562 leukemia cells in vitro.
Yalowich JC; Zucali JR; Gross M; Ross WE
Cancer Res; 1985 Oct; 45(10):4921-4. PubMed ID: 3861238
[TBL] [Abstract][Full Text] [Related]
14. Effects of oxazaphosphorine cytostatics on granuloid progenitor cell (CFUc) proliferation in mice.
Semont H; Hecquet C; Adolphe M; Deysson G
Exp Hematol; 1982 Oct; 10(9):782-8. PubMed ID: 7173344
[TBL] [Abstract][Full Text] [Related]
15. Toxicity of idarubicin and doxorubicin towards normal and leukemic human bone marrow progenitors in relation to their proliferative state.
Minderman H; Linssen P; van der Lely N; Wessels J; Boezeman J; de Witte T; Haanen C
Leukemia; 1994 Mar; 8(3):382-7. PubMed ID: 8127143
[TBL] [Abstract][Full Text] [Related]
16. Cytotoxic activity of an anti-transferrin receptor immunotoxin on normal and leukemic human hematopoietic progenitors.
Cazzola M; Bergamaschi G; Dezza L; D'Uva R; Ponchio L; Rosti V; Ascari E
Cancer Res; 1991 Jan; 51(2):536-41. PubMed ID: 1985771
[TBL] [Abstract][Full Text] [Related]
17. Establishment of a reliable experimental procedure for bone marrow purging with mafosfamide (ASTA Z 7557).
Douay L; Mary JY; Giarratana MC; Najman A; Gorin NC
Exp Hematol; 1989 Jun; 17(5):429-32. PubMed ID: 2653856
[TBL] [Abstract][Full Text] [Related]
18. Cell cycle status of murine megakaryocyte and granulocyte-macrophage colony-forming cells in bone marrow and spleen.
Cen D; Levin J
Exp Hematol; 1992 Oct; 20(9):1094-100. PubMed ID: 1468543
[TBL] [Abstract][Full Text] [Related]
19. 4-Hydroperoxycyclophosphamide inhibits proliferation by human granulocyte-macrophage colony-forming cells (GM-CFC) but spares more primitive progenitor cells.
Gordon MY; Goldman JM; Gordon-Smith EC
Leuk Res; 1985; 9(8):1017-21. PubMed ID: 4046632
[TBL] [Abstract][Full Text] [Related]
20. Density-gradient separation of autologous bone marrow grafts before ex vivo purging with 4-hydroperoxycyclophosphamide.
Rowley SD; Davis JM; Piantadosi S; Jones RJ; Yeager AM; Santos GW
Bone Marrow Transplant; 1990 Nov; 6(5):321-7. PubMed ID: 2291993
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
